A new market report has indicated the medical cannabis industry is set to see remarkable growth over the next four years.

The report, issued by Technavio, a technology research and advisory company, indicates the medical marijuana market will see a compound annual growth rate (CAGR) of 21 percent between 2018 until 2022.

“The increasing use of cannabis for medical purposes is a major factor driving the market’s growth,” Technavio said in its announcement.

When it comes to the expansion of cannabis for medical purposes, the main market driving this growth will be North America, according to the report.

“Owing to the growing consumption of medical marijuana, the region will offer the maximum growth opportunities to the companies in this medical marijuana market during the next four years,” the abstract for the report said.

Recognition for the potential of the medical cannabis market

In an interview with the Investing News Network (INN) Neil Closner, CEO of MedReleaf (TSX:LEAF) confirmed he views the international medical cannabis market as the largest option available for companies in the space.

If you look to countries that are moving towards [legalization of medical cannabis,] many of them are larger than Canada is and many of them will have full government covered cannabis for medical purposes,” Closner said.

He offered Germany as an example of a country with a population of  80 million with full insurance coverage.

David Argudo, CEO of High Hampton Holdings (CSE:HC) said in an interview with INN at the Lift Cannabis Expo in Vancouver earlier this year he expects the amount of research to be done on cannabis to escalate.

“I think we are going to see more [cannabis research data] even sooner than 15 years,” Argudo told INN. “I think that there is a lot of data out there already.”

Investor Takeaway

As the cannabis industry begins to gain legitimacy across the globe, more research is expected to take place and provide answers to what the drug is actually capable of doing as a treatment for patients.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: High Hampton Holdings is a client of the Investing News Network. This article is not paid-for content.

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less